Stox
50
Suven Life Sciences Limited
NSE: SUVEN · Healthcare
₹264.85-4.07%06 Nov 2026
Check figures: unusual quarterly results in SEP '26 (₹-106.94 cr vs a typical ₹5.25 cr). This may be a filing error (e.g. lakh filed as crore) or a genuine one-off; figures are shown as filed. Trailing-twelve-month figures include it.
Ask the data
Instant answers about Suven Life Sciences Limited — computed from its filings, no language modelMarket cap₹7,484 cr
Current price₹264.85
High / Low₹392 / ₹127
P/E—
P/B16.50
Book value₹16.1
ROE-84.2%
ROCE-84.0%
Debt / equity0.00
Dividend yield—
EPS (TTM)₹-13.52
Face value₹1
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY18 | FY20 | FY21 | FY22 | FY23 | FY24 | FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | 625.3 | 14.4 | 13.5 | 11.8 | 13.5 | 11.7 | 7.1 |
| EBITDA | 198.2 | -115.7 | -80.1 | -122.4 | -125.9 | -128.0 | -284.5 |
| Operating margin | 31.7% | -803.1% | -594.0% | -1033.7% | -929.7% | -1095.0% | -4001.4% |
| Interest | 4.6 | 0.6 | 0.8 | 0.5 | 0.3 | 0.2 | 0.2 |
| Depreciation | 21.3 | 4.2 | 4.3 | 4.4 | 6.5 | 6.5 | 5.6 |
| Profit before tax | 195.5 | -106.4 | -77.5 | -122.0 | -118.3 | -106.1 | -276.3 |
| Tax | 71.8 | -12.2 | -5.3 | 0.0 | 0.0 | -1.0 | 0.0 |
| Net profit | 123.7 | -94.2 | 0.0 | 0.0 | 0.0 | -105.1 | -276.3 |
| EPS ₹ | 9.70 | -2.01 | -5.67 | -9.57 | -6.63 | -4.82 | -12.13 |
| Operating cash flow | — | — | — | -127.5 | -207.9 | -82.6 | -301.8 |
| Capex | — | — | — | 19.8 | 2.9 | -2.4 | 5.1 |
| Dividend paid | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Total assets | — | — | — | — | 388.9 | 284.9 | 624.2 |
| Equity | — | — | — | — | 375.3 | 270.0 | 591.4 |
Quarterly performance
last 30 quarters · ₹ crore| MAR '18 | JUN '19 | SEP '19 | DEC '19 | MAR '20 | JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 625.3 | 199.0 | 274.3 | 2.8 | 8.7 | 1.4 | 9.0 | 1.5 | 1.6 | 2.0 | 1.2 | 4.4 | 4.2 | 3.5 | 4.4 | 3.0 | 2.6 | 3.8 | 3.1 | 2.5 | 2.4 | 1.0 | 2.6 | 1.6 | 1.9 | 0.9 | 2.8 | 1.5 | 3.6 | 1.2 |
| Operating profit | 198.2 | 59.4 | 102.0 | -27.7 | -25.1 | -14.2 | -17.6 | -26.6 | -21.6 | -42.6 | -27.6 | -32.5 | -19.7 | -21.1 | -21.7 | -51.6 | -31.5 | -28.0 | -23.5 | -46.2 | -30.3 | -30.5 | -52.2 | -39.2 | -50.8 | -79.8 | -103.3 | -50.6 | -132.5 | -110.9 |
| Operating margin | 31.7% | 29.9% | 37.2% | -998.9% | -289.5% | -993.0% | -195.9% | -1762.3% | -1383.3% | -2118.4% | -2340.7% | -733.2% | -467.3% | -595.5% | -494.3% | -1719.7% | -1207.7% | -737.1% | -768.3% | -1885.3% | -1267.4% | -3023.8% | -2031.5% | -2435.4% | -2713.9% | -8670.7% | -3677.9% | -3330.9% | -3711.5% | -9243.3% |
| Other income | 23.3 | 3.0 | 5.6 | 5.9 | 3.0 | 2.5 | 2.3 | 1.6 | 1.3 | 4.6 | 0.5 | 0.1 | 0.1 | 0.4 | 0.2 | 2.2 | 5.6 | 5.6 | 5.1 | 6.1 | 4.3 | 4.0 | 4.0 | 1.6 | 0.6 | 3.8 | 2.8 | 6.8 | 7.5 | 6.7 |
| Interest | 4.6 | 1.7 | 2.3 | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.5 | 0.5 |
| Depreciation | 21.3 | 5.5 | 5.6 | 0.8 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.0 | 1.0 | 1.2 | 1.1 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.4 | 1.3 | 1.4 | 1.6 | 2.2 | 2.3 |
| Profit before tax | 195.5 | 55.2 | 99.7 | -22.8 | -23.4 | -13.0 | -16.6 | -26.3 | -21.6 | -39.2 | -28.3 | -33.7 | -20.8 | -16.3 | -23.2 | -51.1 | -27.6 | -24.1 | -12.7 | -41.8 | -27.5 | -28.0 | -49.6 | -39.1 | -51.5 | -77.3 | -101.9 | -45.6 | -127.6 | -106.9 |
| Tax | 71.8 | 29.0 | 36.4 | 0.0 | 2.2 | -2.5 | -1.0 | -1.9 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net profit | 123.7 | 26.2 | 63.3 | -22.8 | -25.6 | -10.5 | -15.7 | -24.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -23.2 | -51.1 | 0.0 | 0.0 | 0.0 | 0.0 | -26.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -101.9 | -45.6 | -127.6 | -106.9 |
| EPS ₹ | 9.70 | 2.06 | 4.97 | -1.79 | -2.01 | -0.82 | -1.23 | -1.92 | -1.70 | -3.08 | -2.22 | -2.65 | -1.63 | -1.12 | -1.59 | -2.90 | -1.17 | -1.10 | -0.58 | -1.92 | -1.22 | -1.29 | -2.27 | -1.79 | -2.36 | -3.48 | -4.55 | -2.02 | -4.84 | -3.77 |
| Revenue YoY | — | — | — | — | — | -99.3% | -96.7% | -45.5% | -82.0% | 40.6% | -86.9% | 193.4% | 170.5% | 76.1% | 272.0% | -32.3% | -38.2% | 7.3% | -30.3% | -18.3% | -8.4% | -73.4% | -16.0% | -34.3% | 85.1% | -64.2% | 74.5% | — | 90.9% | 30.4% |
| Profit YoY | — | — | — | — | — | -140.0% | -124.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Earlier results (standalone, Sep '07 – Dec '17)
₹ crore · from BSE, before the NSE XBRL filings beginSuven Life Sciences Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.
Full years
| FY09† | FY10† | FY11† | FY12† | FY13† | FY14† | FY15† | FY16† | FY17† | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.8 | 129.3 | 150.4 | 203.8 | 257.9 | 510.3 | 520.9 | 499.5 | 544.5 |
| Operating profit | 16.3 | 12.6 | 11.8 | 21.1 | 53.2 | 216.8 | 169.1 | 123.3 | 165.3 |
| Operating margin | 11.6% | 9.7% | 7.8% | 10.4% | 20.6% | 42.5% | 32.5% | 24.7% | 30.4% |
| Other income | 5.3 | 0.5 | 2.2 | — | 1.1 | 5.3 | 8.6 | 19.4 | 21.1 |
| Interest | 5.6 | 4.0 | 5.3 | 8.3 | 13.5 | 10.5 | 4.7 | 5.4 | 5.7 |
| Depreciation | 5.0 | 5.3 | 5.5 | 5.5 | 7.9 | 8.8 | 9.8 | 16.7 | 21.4 |
| Profit before tax | 5.1 | 3.7 | 3.2 | 10.7 | 32.9 | 202.7 | 151.6 | 120.5 | 159.4 |
| Tax | -2.0 | -3.3 | -7.2 | -4.8 | 2.0 | 58.6 | 42.8 | 25.5 | 35.9 |
| Net profit | 7.1 | 7.0 | 10.4 | 15.5 | 30.8 | 144.2 | 108.8 | 95.0 | 123.5 |
Quarters
| SEP '07† | DEC '07† | MAR '08† | JUN '08† | SEP '08† | DEC '08† | MAR '09† | JUN '09† | SEP '09† | DEC '09† | MAR '10† | JUN '10† | SEP '10† | DEC '10† | MAR '11† | JUN '11† | SEP '11† | DEC '11† | MAR '12† | JUN '12† | SEP '12† | DEC '12† | MAR '13† | JUN '13† | SEP '13† | DEC '13† | MAR '14† | JUN '14† | SEP '14† | DEC '14† | MAR '15† | JUN '15† | SEP '15† | DEC '15† | MAR '16† | JUN '16† | SEP '16† | DEC '16† | MAR '17† | JUN '17† | SEP '17† | DEC '17† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.8 | 28.4 | 35.0 | 31.2 | 38.3 | 34.8 | 36.4 | 31.0 | 33.2 | 28.9 | 36.2 | 35.9 | 36.9 | 31.9 | 45.6 | 44.6 | 48.0 | 48.6 | 62.5 | 70.5 | 50.3 | 62.4 | 74.7 | 108.7 | 151.4 | 119.4 | 130.8 | 141.5 | 139.8 | 128.8 | 110.7 | 101.0 | 116.8 | 112.5 | 169.3 | 133.2 | 115.5 | 115.5 | 180.2 | 141.0 | 106.9 | 163.7 |
| Operating profit | 0.7 | 3.8 | 3.8 | 2.8 | 7.6 | 1.5 | 4.4 | 4.2 | 4.1 | 1.9 | 2.3 | 4.2 | 2.3 | 0.7 | 4.6 | 5.2 | 2.4 | 0.6 | 13.0 | 13.3 | 11.4 | 14.9 | 13.6 | 43.0 | 71.4 | 54.9 | 47.4 | 57.9 | 38.4 | 48.3 | 24.5 | 25.0 | 30.7 | 24.6 | 42.9 | 43.4 | 36.9 | 36.9 | 48.2 | 45.3 | 45.0 | 51.4 |
| Operating margin | 2.6% | 13.2% | 10.9% | 8.9% | 19.9% | 4.2% | 12.1% | 13.5% | 12.3% | 6.7% | 6.5% | 11.6% | 6.3% | 2.3% | 10.0% | 11.6% | 5.0% | 1.2% | 20.8% | 18.9% | 22.7% | 23.8% | 18.2% | 39.6% | 47.2% | 46.0% | 36.3% | 40.9% | 27.5% | 37.5% | 22.1% | 24.8% | 26.3% | 21.9% | 25.3% | 32.6% | 31.9% | 31.9% | 26.7% | 32.1% | 42.1% | 31.4% |
| Other income | 2.1 | 0.6 | 0.2 | 1.1 | 0.8 | 0.2 | 3.3 | 0.3 | 0.0 | 0.0 | 0.2 | 0.4 | 1.0 | 0.1 | 0.8 | 0.2 | 1.6 | 1.6 | — | 0.5 | -0.4 | 0.4 | 0.5 | 3.2 | 0.1 | 0.8 | 1.2 | 1.1 | 1.4 | 2.3 | 3.8 | 5.1 | 5.8 | 4.0 | 4.5 | 4.5 | 6.8 | 4.9 | 4.9 | 5.6 | 5.1 | 3.3 |
| Interest | 1.3 | 1.3 | 1.4 | 1.4 | 1.5 | 1.4 | 1.4 | 1.1 | 1.0 | 0.9 | 1.1 | 1.1 | 1.5 | 1.3 | 1.4 | 1.6 | 1.9 | 2.1 | 2.6 | 3.2 | 2.9 | 4.7 | 2.7 | 3.2 | 3.4 | 2.2 | 1.7 | 1.2 | 1.3 | 1.0 | 1.2 | 0.9 | 1.4 | 1.5 | 1.6 | 1.6 | 1.2 | 1.3 | 1.6 | 1.3 | 0.9 | 1.1 |
| Depreciation | 1.0 | 1.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.8 | 1.7 | 2.2 | 2.1 | 2.1 | 2.2 | 2.2 | 2.3 | 2.4 | 2.5 | 2.5 | 2.5 | 2.9 | 4.5 | 4.5 | 4.8 | 4.8 | 4.5 | 4.9 | 7.2 | 5.2 | 5.3 | 5.4 |
| Profit before tax | 0.5 | 1.9 | 1.3 | 1.3 | 5.7 | -1.0 | -0.9 | 2.1 | 1.8 | -0.3 | 0.1 | 2.1 | 0.4 | -1.9 | 2.6 | 2.4 | 0.7 | -1.4 | 9.0 | 8.8 | 6.4 | 8.4 | 9.3 | 40.9 | 65.9 | 51.3 | 44.7 | 51.4 | 32.8 | 44.8 | 22.6 | 26.3 | 30.6 | 22.6 | 41.0 | 41.5 | 37.9 | 35.6 | 44.4 | 44.5 | 43.9 | 48.1 |
| Tax | -0.7 | -0.1 | -0.6 | -0.3 | 0.9 | -1.3 | -1.3 | -0.1 | -0.7 | -1.0 | -1.4 | -1.3 | -1.9 | -3.0 | -0.9 | -1.0 | -1.9 | -2.7 | 0.7 | 0.8 | -0.1 | 0.6 | 0.7 | 11.1 | 20.4 | 14.8 | 12.3 | 16.6 | 7.9 | 12.6 | 5.7 | 6.1 | 5.9 | 4.8 | 8.7 | 8.9 | 11.3 | 11.4 | 4.3 | 14.9 | 12.1 | 13.5 |
| Net profit | 1.2 | 2.0 | 1.9 | 1.6 | 4.8 | 0.3 | 0.3 | 2.2 | 2.5 | 0.7 | 1.6 | 3.5 | 2.3 | 1.1 | 3.5 | 3.4 | 2.6 | 1.3 | 8.3 | 8.0 | 6.5 | 7.8 | 8.6 | 29.8 | 45.5 | 36.4 | 32.4 | 34.7 | 24.8 | 32.2 | 16.9 | 20.2 | 24.7 | 17.7 | 32.3 | 32.6 | 26.6 | 24.3 | 40.1 | 29.6 | 31.8 | 34.6 |
| EPS ₹ | 0.10 | 0.17 | 0.17 | 0.14 | 0.42 | 0.02 | 0.03 | 0.19 | 0.22 | 0.06 | 0.14 | 0.30 | 0.20 | 0.10 | 0.30 | 0.29 | 0.22 | 0.11 | 0.71 | 0.68 | 0.56 | 0.66 | 0.74 | 2.55 | 3.90 | 3.12 | 2.77 | 2.97 | 2.13 | 2.73 | 1.41 | 1.59 | 1.94 | 1.39 | 2.54 | 2.56 | 2.09 | 1.91 | 3.17 | 2.32 | 2.49 | 2.72 |
| Revenue YoY | — | — | — | — | 37.7% | 22.6% | 4.1% | -0.7% | -13.4% | -17.0% | -0.7% | 15.8% | 11.2% | 10.5% | 26.2% | 24.2% | 30.2% | 52.2% | 36.9% | 58.0% | 4.6% | 28.3% | 19.5% | 54.1% | 201.3% | 91.4% | 75.1% | 30.2% | -7.6% | 7.9% | -15.4% | -28.7% | -16.5% | -12.7% | 53.0% | 31.9% | -1.0% | 2.7% | 6.4% | 5.8% | -7.5% | 41.6% |
| Profit YoY | — | — | — | — | 316.4% | -86.1% | -82.0% | 36.3% | -47.8% | 157.1% | 351.4% | 58.3% | -7.5% | 55.6% | 121.5% | -2.6% | 9.9% | 15.2% | 137.4% | 136.9% | 153.5% | 501.6% | 3.9% | 274.0% | 601.8% | 369.5% | 275.6% | 16.7% | -45.5% | -11.5% | -47.7% | -41.8% | -0.4% | -45.0% | 90.5% | 61.0% | 7.4% | 37.0% | 24.1% | -9.2% | 19.5% | 42.6% |
Returns & margins
trailing-twelve-month, per quarter| MAR '20 | JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | -41.0% | -131.6% | -19.8% | -19.8% | -15.1% | 0.0% | -9.8% | -9.8% | -13.8% | -13.8% | -24.9% | -46.5% | -84.2% |
| ROCE | — | — | — | — | — | — | — | — | — | — | -87.9% | -104.3% | -31.4% | -33.5% | -34.1% | -31.3% | -39.2% | -40.7% | -76.1% | -74.8% | -46.7% | -59.5% | -84.0% |
| Net margin | 8.5% | 1.5% | -341.2% | -369.8% | -374.9% | -284.9% | -389.6% | 0.0% | 0.0% | 0.0% | -139.8% | -490.4% | -548.7% | -538.4% | -409.9% | 0.0% | -226.8% | -297.9% | -315.2% | -350.1% | -2071.9% | -3119.4% | -4198.6% |
| EBITDA margin | 22.4% | 12.2% | -387.0% | -405.6% | -593.3% | -770.7% | -1891.2% | -1353.6% | -1033.8% | -754.7% | -572.9% | -753.1% | -929.8% | -962.5% | -1079.6% | -1084.1% | -1094.0% | -1465.0% | -1891.1% | -2008.6% | -3995.8% | -4152.5% | -4367.0% |
| Debt / equity | — | — | — | — | — | — | — | — | — | — | 0.89 | 0.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest coverage | 26.23 | 15.29 | -92.51 | -88.07 | -85.09 | -123.98 | -159.25 | -182.24 | -229.19 | -205.50 | -234.00 | -336.67 | -421.39 | -546.96 | -576.65 | -588.83 | -661.94 | -845.31 | -1335.18 | -1803.25 | -1726.19 | -549.69 | -346.34 |
| Asset turnover | — | — | — | — | — | — | — | — | — | — | 0.14 | 0.13 | 0.03 | 0.04 | 0.04 | 0.03 | 0.04 | 0.03 | 0.04 | 0.04 | 0.01 | 0.01 | 0.02 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '22 | MAR '23 | SEP '23 | MAR '24 | SEP '24 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|
| Share capital | 14.5 | 21.8 | 21.8 | 21.8 | 21.8 | 22.8 | 26.4 | 28.3 |
| Other equity / reserves | 41.9 | 353.5 | 316.6 | 248.2 | 170.9 | 258.5 | 565.0 | 425.3 |
| Total equity | 56.5 | 375.3 | 338.4 | 270.0 | 192.7 | 281.3 | 591.4 | 453.6 |
| Borrowings | 50.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 |
| Current liabilities | 60.6 | 11.1 | 9.8 | 13.5 | 17.9 | 54.4 | 30.9 | 39.5 |
| Non-current liabilities | 3.5 | 2.5 | 2.0 | 1.4 | 1.4 | 1.7 | 1.9 | 13.3 |
| Total assets | 120.6 | 388.9 | 350.3 | 284.9 | 212.0 | 337.4 | 624.2 | 506.4 |
| Property, plant & equipment | 36.3 | 35.7 | 33.1 | 27.5 | 25.0 | 58.1 | 55.7 | 89.9 |
| Capital work-in-progress | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 | 3.6 | 4.1 |
| Investments | 45.1 | 46.3 | 64.4 | 75.9 | 74.0 | 246.7 | 0.0 | 13.7 |
| Inventories | 0.0 | 0.0 | 0.7 | 0.7 | 0.7 | 0.2 | 0.1 | 0.1 |
| Receivables | 1.3 | 0.8 | 1.0 | 1.3 | 1.5 | 1.1 | 1.5 | 1.5 |
| Cash & equivalents | 16.8 | 37.0 | 18.6 | 14.9 | 7.4 | 9.6 | 8.3 | 24.1 |
Cash flow
annual · ₹ crore · line = free cash flow| FY22 | FY23 | FY24 | FY26 | |
|---|---|---|---|---|
| Cash from operations | -127.5 | -207.9 | -82.6 | -301.8 |
| Cash from investing | -22.2 | -155.7 | 61.6 | -462.1 |
| Cash from financing | 145.7 | 395.5 | -1.1 | 757.1 |
| Capex | 19.8 | 2.9 | -2.4 | 5.1 |
| Free cash flow | -147.3 | -210.8 | -80.2 | -306.9 |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 |
Where the assets sit
Sep '26 · ₹ croreFixed assets (PPE)₹89.9 cr18%
CWIP₹4.1 cr1%
Investments₹13.7 cr3%
Inventories₹0.1 cr0%
Receivables₹1.5 cr0%
Cash & equivalents₹24.1 cr5%
Other assets₹373.0 cr74%
Peer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Suven Life Sciences Limited | 7,484 | 264.85 | — | 16.50 | -84.2% |
StoxGud checklist: Neutral setup · 5/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month-13.3%
6 months+20.2%
1 year+36.3%
3Y CAGR+48.4%
5Y CAGR+21.3%
10Y CAGR+4.0%
50-day avg₹317.30
200-day avg₹250.93
RSI (14)32
FAQs
What is the share price of Suven Life Sciences Limited?
Suven Life Sciences Limited (SUVEN) closed at ₹264.85 on NSE on 06 Nov 2026.
What is the market cap of Suven Life Sciences Limited?
₹7,484 crore at the latest close.
How fast is Suven Life Sciences Limited growing?
Suven Life Sciences Limited: revenue has compounded at -15.6% a year over three years. Latest-quarter revenue is up 30.4% year on year.
How profitable is Suven Life Sciences Limited?
On a trailing-twelve-month basis return on equity is -84.2%, return on capital employed -84.0%, operating margin -4,367.0%, net margin -4,198.6%.
How much debt does Suven Life Sciences Limited have?
Suven Life Sciences Limited is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹24 cr (balance sheet of 2026-09-30). Operating profit covers interest -346.3 times.
Financials parsed from Suven Life Sciences Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.
Suven Life Sciences Limited · advanced chart